FREDUN vs SYMBIOTEC: Stock Comparison

FREDUN PHARMACEUTICALS L vs SYMBIOTEC PHARMALABUpdated 17 Sept 26, 12:10 PM ISTNSE & company filings

FREDUN PHARMACEUTICALS L shows a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

FREDUN leads 1; SYMBIOTEC leads 0 of 4

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

FREDUNSYMBIOTEC

Valuation lens

What price are you paying?

Market CapContext only
₹0 Cr
₹6,624 Cr
P/E RatioSame reading
0x
P/B RatioSame reading
0x
EPSSame reading
₹7.94
Book ValueContext only
₹168.16
Dividend YieldFREDUN has the higher reading
0.11%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Dividend Yield
FREDUN has a higher dividend yield
0.11% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricFREDUNSYMBIOTEC
Live Price₹1,280₹1,036
Day Change4.78%-0.65%
Volume97,9842.72 L
52-Week High₹1,590₹1,193.7
52-Week Low₹1,195.2₹934.2
Distance from 52W High-19.5%-13.21%

Valuation

MetricFREDUNSYMBIOTEC
Market Cap₹0 Cr₹6,624 Cr
P/E Ratio0x
P/B Ratio0x
EPS₹7.94
Book Value₹168.16
Dividend Yield0.11%0%

Growth

MetricFREDUNSYMBIOTEC
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth0%
Qtr Profit Growth-0.27%

Profitability & Leverage

MetricFREDUNSYMBIOTEC
Net Margin0%0%

Shareholding

As of Jun 2026 • change vs previous quarter
MetricFREDUNSYMBIOTEC
Promoter Holding44.57% 0.4 pp33.28%
FII Holding1.06%21.08%
DII Holding2.94% 0.11 pp27.52%
Public Holding51.43% 0.51 pp18.12%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FREDUN PHARMACEUTICALS L and SYMBIOTEC PHARMALAB.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.